nodes	percent_of_prediction	percent_of_DWPC	metapath
Carbimazole—TPO—Hematopoietic Stem Cell Differentiation—FLI1—bone cancer	0.146	0.35	CbGpPWpGaD
Carbimazole—CYP19A1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.042	0.1	CbGpPWpGaD
Carbimazole—TPO—Hematopoietic Stem Cell Differentiation—IL3—bone cancer	0.0382	0.0913	CbGpPWpGaD
Carbimazole—TPO—Differentiation Pathway—IL3—bone cancer	0.033	0.0789	CbGpPWpGaD
Carbimazole—TPO—Differentiation Pathway—KIT—bone cancer	0.0193	0.0461	CbGpPWpGaD
Carbimazole—CYP19A1—Metapathway biotransformation—CYP4V2—bone cancer	0.0181	0.0432	CbGpPWpGaD
Carbimazole—Ageusia—Cisplatin—bone cancer	0.0173	0.0297	CcSEcCtD
Carbimazole—Infection—Carboplatin—bone cancer	0.0169	0.0291	CcSEcCtD
Carbimazole—Hepatocellular injury—Cisplatin—bone cancer	0.014	0.0241	CcSEcCtD
Carbimazole—Body temperature increased—Carboplatin—bone cancer	0.0135	0.0232	CcSEcCtD
Carbimazole—Bone marrow depression—Methotrexate—bone cancer	0.0114	0.0196	CcSEcCtD
Carbimazole—Liver disorder—Methotrexate—bone cancer	0.0113	0.0194	CcSEcCtD
Carbimazole—Haemolytic anaemia—Cisplatin—bone cancer	0.0113	0.0194	CcSEcCtD
Carbimazole—Bone marrow depression—Epirubicin—bone cancer	0.0107	0.0183	CcSEcCtD
Carbimazole—CYP19A1—Tryptophan metabolism—CYP3A4—bone cancer	0.0104	0.0249	CbGpPWpGaD
Carbimazole—Bone marrow depression—Doxorubicin—bone cancer	0.00987	0.017	CcSEcCtD
Carbimazole—Ageusia—Epirubicin—bone cancer	0.00889	0.0153	CcSEcCtD
Carbimazole—CYP19A1—Ovarian Infertility Genes—CDK4—bone cancer	0.00863	0.0206	CbGpPWpGaD
Carbimazole—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00842	0.0201	CbGpPWpGaD
Carbimazole—Pancytopenia—Cisplatin—bone cancer	0.00835	0.0144	CcSEcCtD
Carbimazole—CYP19A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00831	0.0199	CbGpPWpGaD
Carbimazole—Ageusia—Doxorubicin—bone cancer	0.00822	0.0141	CcSEcCtD
Carbimazole—Jaundice cholestatic—Epirubicin—bone cancer	0.00819	0.0141	CcSEcCtD
Carbimazole—Stomatitis—Cisplatin—bone cancer	0.00764	0.0131	CcSEcCtD
Carbimazole—Jaundice cholestatic—Doxorubicin—bone cancer	0.00758	0.013	CcSEcCtD
Carbimazole—Aplastic anaemia—Methotrexate—bone cancer	0.00722	0.0124	CcSEcCtD
Carbimazole—Hepatocellular injury—Epirubicin—bone cancer	0.0072	0.0124	CcSEcCtD
Carbimazole—TPO—Metabolism—NDUFA12—bone cancer	0.00713	0.017	CbGpPWpGaD
Carbimazole—Mouth ulceration—Methotrexate—bone cancer	0.00695	0.012	CcSEcCtD
Carbimazole—CYP19A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00682	0.0163	CbGpPWpGaD
Carbimazole—Aplastic anaemia—Epirubicin—bone cancer	0.00676	0.0116	CcSEcCtD
Carbimazole—Hepatocellular injury—Doxorubicin—bone cancer	0.00666	0.0115	CcSEcCtD
Carbimazole—Mouth ulceration—Epirubicin—bone cancer	0.00651	0.0112	CcSEcCtD
Carbimazole—Aplastic anaemia—Doxorubicin—bone cancer	0.00625	0.0108	CcSEcCtD
Carbimazole—Alopecia—Cisplatin—bone cancer	0.00622	0.0107	CcSEcCtD
Carbimazole—Mouth ulceration—Doxorubicin—bone cancer	0.00602	0.0104	CcSEcCtD
Carbimazole—TPO—Metabolism—NT5C3A—bone cancer	0.00591	0.0141	CbGpPWpGaD
Carbimazole—Ill-defined disorder—Cisplatin—bone cancer	0.00569	0.00977	CcSEcCtD
Carbimazole—Malaise—Cisplatin—bone cancer	0.00553	0.0095	CcSEcCtD
Carbimazole—Leukopenia—Cisplatin—bone cancer	0.00549	0.00943	CcSEcCtD
Carbimazole—Myalgia—Cisplatin—bone cancer	0.00522	0.00897	CcSEcCtD
Carbimazole—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00518	0.00891	CcSEcCtD
Carbimazole—Liver function test abnormal—Methotrexate—bone cancer	0.00515	0.00886	CcSEcCtD
Carbimazole—Discomfort—Cisplatin—bone cancer	0.00515	0.00886	CcSEcCtD
Carbimazole—Infection—Cisplatin—bone cancer	0.00497	0.00854	CcSEcCtD
Carbimazole—Nervous system disorder—Cisplatin—bone cancer	0.0049	0.00843	CcSEcCtD
Carbimazole—Thrombocytopenia—Cisplatin—bone cancer	0.0049	0.00842	CcSEcCtD
Carbimazole—Skin disorder—Cisplatin—bone cancer	0.00486	0.00835	CcSEcCtD
Carbimazole—Liver function test abnormal—Epirubicin—bone cancer	0.00482	0.00829	CcSEcCtD
Carbimazole—CYP19A1—Tryptophan metabolism—MDM2—bone cancer	0.00479	0.0114	CbGpPWpGaD
Carbimazole—Eosinophilia—Methotrexate—bone cancer	0.00478	0.00821	CcSEcCtD
Carbimazole—Pancytopenia—Methotrexate—bone cancer	0.00458	0.00788	CcSEcCtD
Carbimazole—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00456	0.00783	CcSEcCtD
Carbimazole—Neutropenia—Methotrexate—bone cancer	0.00451	0.00776	CcSEcCtD
Carbimazole—Eosinophilia—Epirubicin—bone cancer	0.00447	0.00769	CcSEcCtD
Carbimazole—Liver function test abnormal—Doxorubicin—bone cancer	0.00446	0.00767	CcSEcCtD
Carbimazole—Pancytopenia—Epirubicin—bone cancer	0.00429	0.00737	CcSEcCtD
Carbimazole—Neutropenia—Epirubicin—bone cancer	0.00422	0.00726	CcSEcCtD
Carbimazole—Stomatitis—Methotrexate—bone cancer	0.00419	0.00721	CcSEcCtD
Carbimazole—Eosinophilia—Doxorubicin—bone cancer	0.00414	0.00711	CcSEcCtD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.00413	0.00986	CbGpPWpGaD
Carbimazole—Feeling abnormal—Cisplatin—bone cancer	0.00412	0.00709	CcSEcCtD
Carbimazole—Agranulocytosis—Methotrexate—bone cancer	0.00402	0.0069	CcSEcCtD
Carbimazole—Pancytopenia—Doxorubicin—bone cancer	0.00397	0.00682	CcSEcCtD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.00397	0.00949	CbGpPWpGaD
Carbimazole—Body temperature increased—Cisplatin—bone cancer	0.00395	0.0068	CcSEcCtD
Carbimazole—Jaundice—Epirubicin—bone cancer	0.00393	0.00675	CcSEcCtD
Carbimazole—Stomatitis—Epirubicin—bone cancer	0.00393	0.00675	CcSEcCtD
Carbimazole—Neutropenia—Doxorubicin—bone cancer	0.00391	0.00672	CcSEcCtD
Carbimazole—Haemoglobin—Methotrexate—bone cancer	0.00388	0.00667	CcSEcCtD
Carbimazole—Haemorrhage—Methotrexate—bone cancer	0.00386	0.00664	CcSEcCtD
Carbimazole—Hepatitis—Methotrexate—bone cancer	0.00386	0.00664	CcSEcCtD
Carbimazole—Agranulocytosis—Epirubicin—bone cancer	0.00376	0.00646	CcSEcCtD
Carbimazole—Hypersensitivity—Cisplatin—bone cancer	0.00368	0.00633	CcSEcCtD
Carbimazole—Haemoglobin—Epirubicin—bone cancer	0.00363	0.00625	CcSEcCtD
Carbimazole—Jaundice—Doxorubicin—bone cancer	0.00363	0.00624	CcSEcCtD
Carbimazole—Stomatitis—Doxorubicin—bone cancer	0.00363	0.00624	CcSEcCtD
Carbimazole—CYP19A1—Biological oxidations—CYP3A4—bone cancer	0.00362	0.00866	CbGpPWpGaD
Carbimazole—Haemorrhage—Epirubicin—bone cancer	0.00361	0.00621	CcSEcCtD
Carbimazole—Hepatitis—Epirubicin—bone cancer	0.00361	0.00621	CcSEcCtD
Carbimazole—CYP19A1—Metapathway biotransformation—CYP3A4—bone cancer	0.00358	0.00855	CbGpPWpGaD
Carbimazole—Angiopathy—Methotrexate—bone cancer	0.0035	0.00603	CcSEcCtD
Carbimazole—Agranulocytosis—Doxorubicin—bone cancer	0.00348	0.00598	CcSEcCtD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.00344	0.00822	CbGpPWpGaD
Carbimazole—Alopecia—Methotrexate—bone cancer	0.00341	0.00587	CcSEcCtD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.00336	0.00804	CbGpPWpGaD
Carbimazole—Haemoglobin—Doxorubicin—bone cancer	0.00336	0.00578	CcSEcCtD
Carbimazole—Haemorrhage—Doxorubicin—bone cancer	0.00334	0.00575	CcSEcCtD
Carbimazole—Hepatitis—Doxorubicin—bone cancer	0.00334	0.00575	CcSEcCtD
Carbimazole—Angiopathy—Epirubicin—bone cancer	0.00328	0.00564	CcSEcCtD
Carbimazole—Alopecia—Epirubicin—bone cancer	0.00319	0.00549	CcSEcCtD
Carbimazole—Rash—Cisplatin—bone cancer	0.00315	0.00542	CcSEcCtD
Carbimazole—Dermatitis—Cisplatin—bone cancer	0.00315	0.00542	CcSEcCtD
Carbimazole—Ill-defined disorder—Methotrexate—bone cancer	0.00312	0.00536	CcSEcCtD
Carbimazole—CYP19A1—Biological oxidations—GSTP1—bone cancer	0.0031	0.00741	CbGpPWpGaD
Carbimazole—CYP19A1—Metapathway biotransformation—GSTP1—bone cancer	0.00306	0.00731	CbGpPWpGaD
Carbimazole—Angiopathy—Doxorubicin—bone cancer	0.00303	0.00522	CcSEcCtD
Carbimazole—Malaise—Methotrexate—bone cancer	0.00303	0.00521	CcSEcCtD
Carbimazole—Leukopenia—Methotrexate—bone cancer	0.00301	0.00517	CcSEcCtD
Carbimazole—Nausea—Cisplatin—bone cancer	0.00297	0.00511	CcSEcCtD
Carbimazole—Alopecia—Doxorubicin—bone cancer	0.00296	0.00508	CcSEcCtD
Carbimazole—Ill-defined disorder—Epirubicin—bone cancer	0.00292	0.00502	CcSEcCtD
Carbimazole—Myalgia—Methotrexate—bone cancer	0.00286	0.00492	CcSEcCtD
Carbimazole—Arthralgia—Methotrexate—bone cancer	0.00286	0.00492	CcSEcCtD
Carbimazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00284	0.00489	CcSEcCtD
Carbimazole—Malaise—Epirubicin—bone cancer	0.00284	0.00488	CcSEcCtD
Carbimazole—Discomfort—Methotrexate—bone cancer	0.00283	0.00486	CcSEcCtD
Carbimazole—Leukopenia—Epirubicin—bone cancer	0.00282	0.00484	CcSEcCtD
Carbimazole—Infection—Methotrexate—bone cancer	0.00273	0.00469	CcSEcCtD
Carbimazole—Ill-defined disorder—Doxorubicin—bone cancer	0.0027	0.00464	CcSEcCtD
Carbimazole—Nervous system disorder—Methotrexate—bone cancer	0.00269	0.00463	CcSEcCtD
Carbimazole—Thrombocytopenia—Methotrexate—bone cancer	0.00269	0.00462	CcSEcCtD
Carbimazole—Myalgia—Epirubicin—bone cancer	0.00268	0.00461	CcSEcCtD
Carbimazole—Arthralgia—Epirubicin—bone cancer	0.00268	0.00461	CcSEcCtD
Carbimazole—Skin disorder—Methotrexate—bone cancer	0.00267	0.00458	CcSEcCtD
Carbimazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00266	0.00457	CcSEcCtD
Carbimazole—Discomfort—Epirubicin—bone cancer	0.00265	0.00455	CcSEcCtD
Carbimazole—Malaise—Doxorubicin—bone cancer	0.00263	0.00451	CcSEcCtD
Carbimazole—Leukopenia—Doxorubicin—bone cancer	0.00261	0.00448	CcSEcCtD
Carbimazole—TPO—Metabolism—ENO2—bone cancer	0.00259	0.00618	CbGpPWpGaD
Carbimazole—Infection—Epirubicin—bone cancer	0.00255	0.00439	CcSEcCtD
Carbimazole—Nervous system disorder—Epirubicin—bone cancer	0.00252	0.00433	CcSEcCtD
Carbimazole—Thrombocytopenia—Epirubicin—bone cancer	0.00251	0.00432	CcSEcCtD
Carbimazole—Musculoskeletal discomfort—Methotrexate—bone cancer	0.0025	0.0043	CcSEcCtD
Carbimazole—Skin disorder—Epirubicin—bone cancer	0.00249	0.00429	CcSEcCtD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.00249	0.00596	CbGpPWpGaD
Carbimazole—Arthralgia—Doxorubicin—bone cancer	0.00248	0.00426	CcSEcCtD
Carbimazole—Myalgia—Doxorubicin—bone cancer	0.00248	0.00426	CcSEcCtD
Carbimazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00246	0.00423	CcSEcCtD
Carbimazole—Discomfort—Doxorubicin—bone cancer	0.00245	0.00421	CcSEcCtD
Carbimazole—TPO—Metabolism—DHFR—bone cancer	0.0024	0.00574	CbGpPWpGaD
Carbimazole—Infection—Doxorubicin—bone cancer	0.00236	0.00406	CcSEcCtD
Carbimazole—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00234	0.00402	CcSEcCtD
Carbimazole—Nervous system disorder—Doxorubicin—bone cancer	0.00233	0.00401	CcSEcCtD
Carbimazole—Thrombocytopenia—Doxorubicin—bone cancer	0.00233	0.004	CcSEcCtD
Carbimazole—Skin disorder—Doxorubicin—bone cancer	0.00231	0.00397	CcSEcCtD
Carbimazole—Feeling abnormal—Methotrexate—bone cancer	0.00226	0.00389	CcSEcCtD
Carbimazole—TPO—Metabolism—GNA11—bone cancer	0.00224	0.00536	CbGpPWpGaD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.00221	0.00527	CbGpPWpGaD
Carbimazole—Urticaria—Methotrexate—bone cancer	0.00218	0.00375	CcSEcCtD
Carbimazole—CYP19A1—Metabolism—NDUFA12—bone cancer	0.00217	0.00519	CbGpPWpGaD
Carbimazole—Body temperature increased—Methotrexate—bone cancer	0.00217	0.00373	CcSEcCtD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—RB1—bone cancer	0.00217	0.00518	CbGpPWpGaD
Carbimazole—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00216	0.00372	CcSEcCtD
Carbimazole—Feeling abnormal—Epirubicin—bone cancer	0.00212	0.00364	CcSEcCtD
Carbimazole—Urticaria—Epirubicin—bone cancer	0.00204	0.00351	CcSEcCtD
Carbimazole—TPO—Metabolism—CYP3A4—bone cancer	0.00203	0.00486	CbGpPWpGaD
Carbimazole—Body temperature increased—Epirubicin—bone cancer	0.00203	0.00349	CcSEcCtD
Carbimazole—Hypersensitivity—Methotrexate—bone cancer	0.00202	0.00348	CcSEcCtD
Carbimazole—Feeling abnormal—Doxorubicin—bone cancer	0.00196	0.00337	CcSEcCtD
Carbimazole—Pruritus—Methotrexate—bone cancer	0.00194	0.00334	CcSEcCtD
Carbimazole—Hypersensitivity—Epirubicin—bone cancer	0.00189	0.00325	CcSEcCtD
Carbimazole—Urticaria—Doxorubicin—bone cancer	0.00189	0.00325	CcSEcCtD
Carbimazole—Body temperature increased—Doxorubicin—bone cancer	0.00188	0.00323	CcSEcCtD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.00185	0.00442	CbGpPWpGaD
Carbimazole—Pruritus—Epirubicin—bone cancer	0.00182	0.00312	CcSEcCtD
Carbimazole—CYP19A1—Metabolism—NT5C3A—bone cancer	0.0018	0.0043	CbGpPWpGaD
Carbimazole—Hypersensitivity—Doxorubicin—bone cancer	0.00175	0.00301	CcSEcCtD
Carbimazole—TPO—Metabolism—GSTP1—bone cancer	0.00174	0.00416	CbGpPWpGaD
Carbimazole—Rash—Methotrexate—bone cancer	0.00173	0.00297	CcSEcCtD
Carbimazole—Dermatitis—Methotrexate—bone cancer	0.00173	0.00297	CcSEcCtD
Carbimazole—Headache—Methotrexate—bone cancer	0.00172	0.00296	CcSEcCtD
Carbimazole—Pruritus—Doxorubicin—bone cancer	0.00168	0.00289	CcSEcCtD
Carbimazole—Nausea—Methotrexate—bone cancer	0.00163	0.0028	CcSEcCtD
Carbimazole—Rash—Epirubicin—bone cancer	0.00162	0.00278	CcSEcCtD
Carbimazole—Dermatitis—Epirubicin—bone cancer	0.00162	0.00278	CcSEcCtD
Carbimazole—Headache—Epirubicin—bone cancer	0.00161	0.00277	CcSEcCtD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—JUN—bone cancer	0.00161	0.00384	CbGpPWpGaD
Carbimazole—Nausea—Epirubicin—bone cancer	0.00153	0.00262	CcSEcCtD
Carbimazole—Rash—Doxorubicin—bone cancer	0.0015	0.00258	CcSEcCtD
Carbimazole—Dermatitis—Doxorubicin—bone cancer	0.0015	0.00257	CcSEcCtD
Carbimazole—Headache—Doxorubicin—bone cancer	0.00149	0.00256	CcSEcCtD
Carbimazole—Nausea—Doxorubicin—bone cancer	0.00141	0.00243	CcSEcCtD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.00126	0.00302	CbGpPWpGaD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—TP53—bone cancer	0.00106	0.00254	CbGpPWpGaD
Carbimazole—TPO—Metabolism—PTGS2—bone cancer	0.000901	0.00215	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—ENO2—bone cancer	0.000789	0.00189	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—DHFR—bone cancer	0.000732	0.00175	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—GNA11—bone cancer	0.000684	0.00163	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—CYP3A4—bone cancer	0.00062	0.00148	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000617	0.00147	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—GSTP1—bone cancer	0.00053	0.00127	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—PTGS2—bone cancer	0.000275	0.000657	CbGpPWpGaD
